Xylyx Bio

The cell environment company

Accelerate anti-fibrotic drug development with human disease-specific ECM substrates

Environment matters.

Just as the environment matters at the macro scale for plants and animals, it is essential at the micro scale for cells. Recognizing the importance of the native cellular microenvironment, Xylyx Bio is harnessing the power of tissue-specific extracellular matrix, the body’s native cell environment, for both drug discovery and tissue regeneration.

Cell Culture

Xylyx Bio's suite of native tissue-specific extracellular matrix (ECM) products bring the most physiologic cell environments possible to the petri dish to radically improve early-stage drug discovery efforts.

Tissue Regeneration

With potential to address multiple unmet clinical needs, Xylyx Bio is utilizing its proprietary matrix bioactives to pursue R&D on clinically-oriented products derived from tissue-specific ECM.

News

Xylyx Bio announces development of disease-specific cell culture products to accelerate anti-fibrotic drug discovery and screening

Fibrosis-specific substrates provide a disease-relevant in-vitro testing platform to inform decision-making in early-stage drug discovery. Through the development of fibrosis-specific in-vitro substrates, Xylyx Bio aims to support drug discovery and development for fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH).

Xylyx Bio joins Advanced Regenerative Manufacturing Institute (ARMI) Consortium

Xylyx Bio announced that it has joined the Advanced Regenerative Manufacturing Institute (ARMI), a public-private Manufacturing USA initiative that supports the manufacturing of engineered tissues and tissue-related technologies, with the goal to focus on accelerating the standardization and commercialization of tissue-specific extracellular matrix biomaterials for regenerative medicine and tissue engineering.

Xylyx Bio Announces Global Expansion

Xylyx Bio announced partnerships with 9 international distributors to meet growing demand. Additional distributors provide scientists working in drug screening, cancer research, 3D cell models and toxicology with the ability to improve the human relevance of in vitro cell models.

East River BioSolutions Announces Rebrand to Xylyx Bio

East River BioSolutions, a biotech company specializing in cell-specific extracellular matrix biomaterials, today announced its rebrand to Xylyx Bio. The new branding underscores the Company’s focus on accelerating science for improved human health.

Xylyx Bio announces development of disease-specific cell culture products to accelerate anti-fibrotic drug discovery and screening

Xylyx Bio joins Advanced Regenerative Manufacturing Institute (ARMI) Consortium

What they’re saying

“ We were looking for a product to use for engineering cartilage tissue. We used the TissueSpec® Cartilage ECM Hydrogel to encapsulate chondrocytes within the 3D tissue environment the cells are exposed to in native cartilage. Chondrocytes grew really well, and these tissue constructs have developed mechanical and biochemical properties and histological staining similar to native articular cartilage.”

Bob Nims, PhD, Columbia University

“ As a cancer cell biologist it is always challenging to develop ideal cancer cell culture condition in 3D model to study cell-signaling pathways. Xylyx Bio offers bone and liver derived hydrogels, the two major sites for the prostate cancer metastasis. Those TissueSpec® ECM Hydrogels are a perfect solution to study the effect of metastatic microenvironment on prostate cancer cell signaling. ”

Goutam Chakraborty, Ph.D, MSKCC

“ Though our relationship is new, working with Xylyx Bio has been a pleasure. They are incredibly responsive and helpful with both scientific and non-scientific inquiries and are willing to go above and beyond to work with customers! ”

Amanda Khoo, PhD, Brown University

Xylyx Bio The cell environment company

Accelerate anti-fibrotic drug development with human disease-specific ECM substrates

What they’re saying

Accelerate anti-fibrotic drug development with human disease-specific ECM substrates

Environment matters.

Cell Culture

Tissue Regeneration

News

Xylyx Bio announces development of disease-specific cell culture products to accelerate anti-fibrotic drug discovery and screening

Xylyx Bio joins Advanced Regenerative Manufacturing Institute (ARMI) Consortium

Xylyx Bio Announces Global Expansion

East River BioSolutions Announces Rebrand to Xylyx Bio

Xylyx Bio announces development of disease-specific cell culture products to accelerate anti-fibrotic drug discovery and screening

Xylyx Bio joins Advanced Regenerative Manufacturing Institute (ARMI) Consortium

What they’re saying

Xylyx Bio

The cell environment company